ME03386B - Hibridni laki lanac imunoglobulina koji ispoljavaju miševi - Google Patents

Hibridni laki lanac imunoglobulina koji ispoljavaju miševi

Info

Publication number
ME03386B
ME03386B MEP-2019-128A MEP12819A ME03386B ME 03386 B ME03386 B ME 03386B ME P12819 A MEP12819 A ME P12819A ME 03386 B ME03386 B ME 03386B
Authority
ME
Montenegro
Prior art keywords
vaeiable
human
region
light chain
mice expressing
Prior art date
Application number
MEP-2019-128A
Other languages
German (de)
English (en)
French (fr)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J Murphy
Karolina A Hosiawa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ME03386B publication Critical patent/ME03386B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
MEP-2019-128A 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispoljavaju miševi ME03386B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22
EP16154526.4A EP3034608B1 (en) 2010-06-22 2011-06-22 Mice expressing an immunoglobulin hybrid light chain with a human variable region

Publications (1)

Publication Number Publication Date
ME03386B true ME03386B (me) 2020-01-20

Family

ID=44509861

Family Applications (5)

Application Number Title Priority Date Filing Date
MEP-2016-119A ME02442B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka
MEP-2019-128A ME03386B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispoljavaju miševi
MEP-2016-132A ME02440B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom
MEP-2016-87A ME02444B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispouavaju miševi
MEP-2017-244A ME02902B (me) 2010-06-22 2011-06-22 Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2016-119A ME02442B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka

Family Applications After (3)

Application Number Title Priority Date Filing Date
MEP-2016-132A ME02440B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom
MEP-2016-87A ME02444B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispouavaju miševi
MEP-2017-244A ME02902B (me) 2010-06-22 2011-06-22 Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina

Country Status (30)

Country Link
US (22) US9035128B2 (me)
EP (7) EP2905338B8 (me)
JP (16) JP6009441B2 (me)
KR (16) KR102193823B1 (me)
CN (4) CN104404050B (me)
AU (1) AU2011271046B2 (me)
BR (3) BR122020013427B1 (me)
CA (2) CA2803864C (me)
CY (5) CY1117537T1 (me)
DK (5) DK2568049T3 (me)
ES (5) ES2576928T3 (me)
HR (5) HRP20160794T1 (me)
HU (5) HUE036597T2 (me)
IL (12) IL300712B2 (me)
LT (4) LT2905338T (me)
ME (5) ME02442B (me)
MX (6) MX347318B (me)
MY (6) MY194456A (me)
NO (1) NO2905338T3 (me)
NZ (6) NZ626979A (me)
PL (5) PL2568049T3 (me)
PT (5) PT2568049T (me)
RS (5) RS58736B1 (me)
RU (3) RU2590594C2 (me)
SG (4) SG10201504568YA (me)
SI (5) SI3034608T1 (me)
SM (5) SMT201900241T1 (me)
TR (1) TR201905992T4 (me)
WO (2) WO2011163311A1 (me)
ZA (5) ZA201300062B (me)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
AU2009329365B2 (en) 2008-12-18 2016-01-14 Roger Kingdon Craig Non-human transgenic animals expressing humanised antibodies and use thereof
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
WO2011123708A2 (en) 2010-03-31 2011-10-06 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
CN104404050B (zh) * 2010-06-22 2018-06-08 瑞泽恩制药公司 杂交轻链小鼠
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CA2807282A1 (en) * 2010-08-02 2012-02-09 Regeneron Pharamaceuticals, Inc. Mice that make binding proteins comprising vl domains
FI3865581T3 (fi) 2011-08-05 2024-11-02 Regeneron Pharma Humanisoituja universaaleja kevytketjun hiiriä
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9706759B2 (en) * 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
RS57118B1 (sr) 2012-03-16 2018-06-29 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
CN104302170B (zh) 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
NZ730271A (en) 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2831245A1 (en) 2012-03-28 2015-02-04 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
TR201810255T4 (tr) 2013-02-20 2018-08-27 Regeneron Pharma Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar.
LT3501272T (lt) * 2013-03-13 2023-03-27 Regeneron Pharmaceuticals, Inc. Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką
EP2967012B1 (en) 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
SG11201601272YA (en) * 2013-09-18 2016-03-30 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
US20170101460A1 (en) * 2014-01-10 2017-04-13 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
SG11201607015VA (en) * 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CA2951234C (en) 2014-06-06 2022-05-31 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
AU2015317370A1 (en) 2014-09-19 2017-03-23 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CA2963470A1 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
KR20230125855A (ko) 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
EP3233912B1 (en) 2014-12-19 2021-05-19 Regenesance B.V. Antibodies that bind human c6 and uses thereof
CN110256558B (zh) 2014-12-23 2023-07-04 百时美施贵宝公司 针对tigit的抗体
ES2721775T3 (es) 2015-02-05 2019-08-05 Basf Se Central solar con un primer circuito de portador de calor y un segundo circuito de portador de calor
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
EA201890162A1 (ru) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани Антитела к cd40 с повышенной агонистической активностью
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
EP3411476B1 (en) 2016-02-04 2024-04-24 Trianni, Inc. Enhanced production of immunoglobulins
EP4406550A3 (en) 2016-03-04 2024-10-16 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
KR20220033522A (ko) 2016-03-04 2022-03-16 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CA3023678A1 (en) 2016-05-09 2017-11-16 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
EP4368637A3 (en) 2016-05-20 2024-07-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
KR102784608B1 (ko) 2016-06-03 2025-03-27 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US10650241B2 (en) * 2016-06-27 2020-05-12 Facebook, Inc. Systems and methods for identifying matching content
SG10201911972QA (en) 2016-07-14 2020-02-27 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
CR20190193A (es) 2016-10-13 2019-08-21 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
EP3533867A4 (en) 2016-10-31 2020-07-22 National University Corporation Tottori University NON-HUMAN ANIMAL PRODUCING HUMAN ANTIBODIES AND PROCESS FOR THE PREPARATION OF HUMAN ANTIBODIES USING IT
CN109996441B (zh) * 2016-11-04 2022-02-08 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3720279B1 (en) 2017-12-05 2022-09-21 Regeneron Pharmaceuticals, Inc. Mice having an engineered immunoglobulin lambda light chain and uses thereof
CN111886255B (zh) 2018-01-12 2025-04-04 百时美施贵宝公司 抗tim3抗体及其用途
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
WO2019236670A1 (en) * 2018-06-08 2019-12-12 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain i
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
WO2020085011A1 (ja) 2018-10-26 2020-04-30 ビークルエナジージャパン株式会社 電池制御装置
JP7520003B2 (ja) 2018-11-16 2024-07-22 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
TW202110323A (zh) * 2019-06-05 2021-03-16 美商再生元醫藥公司 具有表現自κ 基因座的有限λ 輕鏈組庫的非人類動物及其用途
ES3027509T3 (en) * 2019-07-01 2025-06-16 Zoetis Services Llc Transgenic rodents and methods of use thereof
CA3163549A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP2023541216A (ja) * 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
CA3199879A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
US12371487B2 (en) 2020-12-23 2025-07-29 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
TW202509069A (zh) 2023-05-04 2025-03-01 美商諾瓦森塔股份有限公司 抗cd161抗體及其使用方法
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
ES2301183T3 (es) * 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) * 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
WO2002092812A1 (fr) * 2001-05-11 2002-11-21 Kirin Beer Kabushiki Kaisha CHROMOSOME HUMAIN ARTIFICIEL CONTENANT LE GENE A CHAINE LEGERE DE L'ANTICORPS HUMAIN $g(l)
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP3269235B1 (en) 2001-11-30 2022-01-26 Amgen Fremont Inc. Transgenic mice bearing human ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
CN1852925A (zh) 2003-07-15 2006-10-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
EP1831257B9 (en) * 2004-12-29 2011-05-04 Yuhan Corporation Humanized antibody specific for tumor necrosis factor-alpha
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US8084024B2 (en) * 2006-08-22 2011-12-27 G2 Inflammation Pty Ltd Method for producing antibodies
PL2069403T3 (pl) 2006-10-02 2015-08-31 Regeneron Pharma Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
CA2721231C (en) * 2008-04-14 2015-10-06 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
KR20110020860A (ko) * 2008-05-23 2011-03-03 알리바 바이오파마수티컬스, 아이엔씨. 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
AU2009329365B2 (en) * 2008-12-18 2016-01-14 Roger Kingdon Craig Non-human transgenic animals expressing humanised antibodies and use thereof
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
ES2603559T5 (es) * 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
CA2802591A1 (en) 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
CN104404050B (zh) * 2010-06-22 2018-06-08 瑞泽恩制药公司 杂交轻链小鼠

Also Published As

Publication number Publication date
ES2570131T3 (es) 2016-05-17
US9844212B2 (en) 2017-12-19
CY1117692T1 (el) 2017-05-17
EP2480676A1 (en) 2012-08-01
MY194456A (en) 2022-11-30
PT3034608T (pt) 2019-05-28
SMT201600229B (me) 2016-08-31
PL2905338T3 (pl) 2018-01-31
KR101970944B1 (ko) 2019-04-23
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
EP2905338B8 (en) 2018-01-24
NZ707198A (en) 2016-04-29
KR102506001B1 (ko) 2023-03-07
DK2905338T3 (da) 2017-11-06
WO2011163314A1 (en) 2011-12-29
EP3456832A1 (en) 2019-03-20
US9066502B2 (en) 2015-06-30
US9394373B2 (en) 2016-07-19
KR102211911B1 (ko) 2021-02-05
BR112012032991B1 (pt) 2021-08-10
US20190153384A1 (en) 2019-05-23
SMT201700506T1 (it) 2018-01-11
ZA201300062B (en) 2014-09-25
MX2012015298A (es) 2013-05-01
EP2480675A1 (en) 2012-08-01
US20150089680A1 (en) 2015-03-26
EP2568049B1 (en) 2016-04-13
IL291301A (en) 2022-05-01
AU2011271043B2 (en) 2015-10-01
DK2480676T3 (en) 2016-06-20
KR20200064166A (ko) 2020-06-05
EP2905338A1 (en) 2015-08-12
PT2480675T (pt) 2016-07-11
ZA201404600B (en) 2015-09-30
JP6009441B2 (ja) 2016-10-19
MY157477A (en) 2016-06-15
CA2803864C (en) 2017-05-16
BR112012032991A8 (pt) 2020-09-29
IL282872A (en) 2021-06-30
NZ626979A (en) 2015-05-29
US9540452B2 (en) 2017-01-10
HRP20160497T1 (hr) 2016-07-15
ME02444B (me) 2016-09-20
US9850462B2 (en) 2017-12-26
JP6341972B2 (ja) 2018-06-13
US9012717B2 (en) 2015-04-21
KR102118565B1 (ko) 2020-06-03
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
JP6243384B2 (ja) 2017-12-06
HUE036597T2 (hu) 2018-07-30
DK2568049T3 (en) 2016-08-01
IL255179A0 (en) 2017-12-31
HUE030285T2 (en) 2017-05-29
JP2017006152A (ja) 2017-01-12
KR20210013376A (ko) 2021-02-03
KR101934852B1 (ko) 2019-01-04
CN103068993B (zh) 2016-01-06
IL259965A (en) 2018-07-31
DK3034608T3 (da) 2019-05-06
IL259965B (en) 2019-02-28
IL223719A (en) 2016-10-31
JP6963542B2 (ja) 2021-11-10
RS58736B1 (sr) 2019-06-28
US9035128B2 (en) 2015-05-19
EP3034608B1 (en) 2019-01-30
KR20220150430A (ko) 2022-11-10
IL300712B1 (en) 2024-07-01
US20150320023A1 (en) 2015-11-12
KR20200143511A (ko) 2020-12-23
MY195214A (en) 2023-01-11
AU2011271043A8 (en) 2016-01-21
US20200239837A1 (en) 2020-07-30
KR20210073609A (ko) 2021-06-18
IL300712A (en) 2023-04-01
EP3034608A1 (en) 2016-06-22
US20240327785A1 (en) 2024-10-03
KR101991234B1 (ko) 2019-06-20
PL2568049T3 (pl) 2017-03-31
ZA201404601B (en) 2016-02-24
HUE029692T2 (en) 2017-03-28
US9206263B2 (en) 2015-12-08
JP2013531501A (ja) 2013-08-08
CY1119478T1 (el) 2018-03-07
JP2020062061A (ja) 2020-04-23
NZ605751A (en) 2014-10-31
IL223720A (en) 2017-05-29
JP5988969B2 (ja) 2016-09-07
PL2480676T3 (pl) 2016-10-31
US20150246976A1 (en) 2015-09-03
US9226484B2 (en) 2016-01-05
ZA201300063B (en) 2014-09-25
US20160057979A1 (en) 2016-03-03
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
US20130326647A1 (en) 2013-12-05
RS56589B1 (sr) 2018-02-28
JP6545773B2 (ja) 2019-07-17
LT2905338T (lt) 2017-12-27
CY1122877T1 (el) 2021-05-05
US20150246977A1 (en) 2015-09-03
PL3034608T3 (pl) 2019-08-30
EP2480675B1 (en) 2016-04-06
MX2022002117A (es) 2022-03-17
US9163092B2 (en) 2015-10-20
SG10201504568YA (en) 2015-07-30
KR102462042B1 (ko) 2022-11-03
CY1118126T1 (el) 2017-06-28
MY195212A (en) 2023-01-11
US20130323790A1 (en) 2013-12-05
US20150173331A1 (en) 2015-06-25
HUE029691T2 (en) 2017-03-28
CA2803864A1 (en) 2011-12-29
IL244450A (en) 2017-11-30
SI2568049T1 (sl) 2016-10-28
EP2905338B1 (en) 2017-08-02
US20170107484A1 (en) 2017-04-20
ZA201506598B (en) 2017-03-29
HRP20190807T1 (hr) 2019-08-23
US20150351371A1 (en) 2015-12-10
DK2480675T3 (en) 2016-08-01
ME02440B (me) 2016-09-20
NO2905338T3 (me) 2017-12-30
JP2016010417A (ja) 2016-01-21
US20140137275A1 (en) 2014-05-15
US20170258059A1 (en) 2017-09-14
PT2480676E (pt) 2016-06-09
IL269078A (en) 2019-11-28
US9150662B2 (en) 2015-10-06
AU2011271046A1 (en) 2013-01-31
MX2012015300A (es) 2013-05-01
RS54891B1 (sr) 2016-10-31
IL255179B (en) 2018-06-28
CN103068994A (zh) 2013-04-24
EP3205726A1 (en) 2017-08-16
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
HK1170766A1 (zh) 2013-03-08
KR20180135996A (ko) 2018-12-21
US9334333B2 (en) 2016-05-10
US9206261B2 (en) 2015-12-08
KR20190014578A (ko) 2019-02-12
RU2601297C2 (ru) 2016-10-27
SMT201900241T1 (it) 2019-05-10
AU2011271043A1 (en) 2013-01-31
KR20230036157A (ko) 2023-03-14
JP2016010415A (ja) 2016-01-21
RU2013102596A (ru) 2014-07-27
JP2017012204A (ja) 2017-01-19
ME02902B (me) 2018-04-20
IL313063A (en) 2024-07-01
RS55037B1 (sr) 2016-12-30
SMT201600212B (it) 2016-08-31
KR20190073584A (ko) 2019-06-26
MX347318B (es) 2017-04-21
ES2575223T3 (es) 2016-06-27
HRP20160865T1 (hr) 2016-10-07
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
SI2905338T1 (sl) 2017-12-29
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
MY165287A (en) 2018-03-21
AU2011271046B2 (en) 2015-10-01
IL291301B1 (en) 2023-03-01
KR20190142436A (ko) 2019-12-26
JP2023133554A (ja) 2023-09-22
IL244450A0 (en) 2016-04-21
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
AU2011271043A9 (en) 2015-10-01
SI2480675T1 (sl) 2016-08-31
KR102059909B1 (ko) 2019-12-27
CA2804311C (en) 2017-09-12
BR122020013427B1 (pt) 2021-08-03
US20160060359A1 (en) 2016-03-03
ME02442B (me) 2016-09-20
BR112012032991A2 (pt) 2015-10-06
KR20130027555A (ko) 2013-03-15
US20120070861A1 (en) 2012-03-22
LT2480675T (lt) 2016-10-10
KR102193823B1 (ko) 2020-12-22
KR20210134424A (ko) 2021-11-09
HUE044001T2 (hu) 2019-09-30
US9399683B2 (en) 2016-07-26
HK1226766A1 (en) 2017-10-06
IL300712B2 (en) 2024-11-01
JP2020128440A (ja) 2020-08-27
RU2724736C2 (ru) 2020-06-25
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
NZ627119A (en) 2015-05-29
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
JP2018201527A (ja) 2018-12-27
US9029628B2 (en) 2015-05-12
CA2804311A1 (en) 2011-12-29
JP2021061863A (ja) 2021-04-22
RU2016119423A3 (me) 2019-11-19
HK1183321A1 (en) 2013-12-20
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
CN103068993A (zh) 2013-04-24
MX348942B (es) 2017-07-04
JP7236409B2 (ja) 2023-03-09
JP6073441B2 (ja) 2017-02-01
RS55042B1 (sr) 2016-12-30
CN104342455A (zh) 2015-02-11
MX347322B (es) 2017-04-21
SI2480676T1 (sl) 2016-10-28
HRP20171666T1 (hr) 2017-12-15
JP2018201528A (ja) 2018-12-27
US20150173332A1 (en) 2015-06-25
ES2646052T3 (es) 2017-12-11
KR20190049932A (ko) 2019-05-09
KR102001430B1 (ko) 2019-07-18
US20190203171A1 (en) 2019-07-04
RU2590594C2 (ru) 2016-07-10
EP2480676B1 (en) 2016-04-06
JP2019033765A (ja) 2019-03-07
SMT201600213B (it) 2016-08-31
ES2576928T3 (es) 2016-07-12
CY1117537T1 (el) 2017-04-26
EP2568049A1 (en) 2013-03-13
CN103068994B (zh) 2016-01-20
NZ707200A (en) 2016-04-29
SG186390A1 (en) 2013-01-30
KR20180135997A (ko) 2018-12-21
CN104404050B (zh) 2018-06-08
US9206262B2 (en) 2015-12-08
CN104342455B (zh) 2017-05-31
BR112012033248A2 (pt) 2017-11-28
MX336344B (es) 2016-01-15
IL291301B2 (en) 2023-07-01
HRP20160794T1 (hr) 2016-08-12
IL264634B (en) 2019-09-26
SG186391A1 (en) 2013-01-30
MY195217A (en) 2023-01-11
SG10201504324UA (en) 2015-07-30
IL247386A (en) 2017-07-31
NZ605758A (en) 2014-08-29
US20150176002A1 (en) 2015-06-25
JP2025027148A (ja) 2025-02-26
CN104404050A (zh) 2015-03-11
US9006511B2 (en) 2015-04-14
RU2013102595A (ru) 2014-07-27
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
JP2018023403A (ja) 2018-02-15
KR101945352B1 (ko) 2019-02-07
TR201905992T4 (tr) 2019-05-21

Similar Documents

Publication Publication Date Title
ME03386B (me) Hibridni laki lanac imunoglobulina koji ispoljavaju miševi
IL290085B2 (en) Mouse with a common light chain
IL233153A0 (en) Mice with human light chain
SG11201405058WA (en) Animals expressing human lambda immunoglobulin light chain variable domain
ZA201505835B (en) Mice expressing a limited immunoglobulin light chain reperoire
PL2384180T3 (pl) Powłoka pieluchy
GB2481036B (en) A vehicle light and a vehicle including at least one vehicle light
PL2585752T3 (pl) Zamykający element zawierający źródło światła
GB201004506D0 (en) Light snack
TWM400936U (en) Light guide
PT2384180E (pt) Capa de fralda